CRMD
CorMedix Inc.
CRMD's fundamentals are mixed, but it looks expensive: trading at 6.6x earnings, above its usual 3.9x. Analysts expect a turn to a loss, though they disagree widely on how much.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
CRMD Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Strong | |
| Strong |
CRMD's revenue, profitability, cash flow and balance sheet are all currently healthy.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
CRMD PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 3.5x | $2.52 | -48% |
| Fair | 3.9x | $2.83 | -41% |
| Current | 6.6x | $4.84 | — |
| Expensive | 18x | $13.42 | +177% |
Historical ranges are pointers, not guarantees.
CRMD's PE is in its expensive range at 6.6x.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
CRMD Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong decline | |
| Strongly weakening | |
| Limited | |
| Low |
Analysts expect CRMD's earnings and revenue to decline, with profitability weakening. However, they disagree widely on these estimates.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
HIMS has the edge over CRMD on the outlook, with more favorable revenue and profitability expectations.
CRMD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $0.73 | -65% |
| Q2 2026 | $2.18 | +179% |
| Q1 2026 | $2.17 | +768% |
| Q4 2025 | $2.04 | +$2.34 |
| Q3 2025 | $2.09 | +$2.89 |
| Q2 2025 | $0.78 | +$1.70 |
| Q1 2025 | $0.25 | +$1.17 |
| Q4 2024 | -$0.30 | +$0.61 |
CRMD has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
CRMD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $54.5M | -48% |
| Q2 2026 | $101.9M | +157% |
| Q1 2026 | $127.4M | +226% |
| Q4 2025 | $128.6M | +312% |
| Q3 2025 | $104.3M | +810% |
| Q2 2025 | $39.7M | +4829% |
| Q4 2022 | $29.7K | -47% |
| Q3 2022 | $6.8K | -82% |
CRMD's revenue is growing: $55M last quarter, down 48% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -12% | -61 points |
| Q2 2026 | 42% | -7.1 points |
| Q1 2026 | 50% | -1.5 points |
| Q4 2025 | 46% | +4.5 points |
| Q3 2025 | 49% | +78 points |
| Q2 2025 | 49% | +1947 points |
| Q1 2025 | 52% | N/A |
| Q4 2024 | 41% | N/A |
CRMD's operating margin was −12% last quarter, down 61 points from the same quarter a year ago.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over CRMD on profitability, with a higher operating margin.
CRMD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $87.8M | +189% |
| Q2 2026 | $85.7M | +186% |
| Q1 2026 | $41.7M | +111% |
| Q4 2025 | $92.7M | +$98.4M |
| Q3 2025 | $30.4M | +$44M |
| Q2 2025 | $30M | +$44M |
| Q1 2025 | $19.7M | +$37.1M |
| Q4 2024 | -$5.6M | +$5.4M |
CRMD has the edge over HIMS on cash flow, with more consistent year-over-year improvement.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS still generates free cash flow, though less than at its 2024 peak: $8M over the past year.
CRMD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -15% | -14M shares |
| 1 year | +9.1% | +6.5M shares |
| 3 years | +73% | +33.1M shares |
| 5 years | +106% | +40.4M shares |
| Available history | +225% | +54.3M shares |
CRMD has 78M diluted shares, up 9.1% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | $6.4M |
| Q1 2026 | $11.1M |
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over CRMD on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
CRMD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.8x | Net Cash |
| Q2 2026 | -1.0x | Net Cash |
| Q1 2026 | -0.8x | Net Cash |
| Q4 2025 | -0.9x | Net Cash |
| Q3 2025 | -0.5x | Net Cash |
| Q2 2025 | -3.2x | Net Cash |
| Q1 2025 | -4.5x | Net Cash |
CRMD has more cash than debt.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
CRMD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 29.4 | Oversold |
| Stochastic | 2.7 | Oversold |
CRMD's weekly RSI is 29 (oversold) and its Stochastic is 3 (oversold).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
CRMD PE vs Healthcare Sector
| Metric | CRMD | Sector median | Relative |
|---|---|---|---|
| PE | 6.6x | 26x | 74% below |
| PE % | 66 | 29 | 37 pts above |
CRMD is trading at 6.6x earnings, a 74% discount to the Healthcare sector's median of 26x.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
CRMD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $6.67 | 27% below |
| 20 week MA | $7.49 | 35% below |
| 50 week MA | $7.91 | 39% below |
| 100 week MA | $9.41 | 49% below |
| 200 week MA | $7.22 | 33% below |
CRMD is in a downtrend: it's below all five of its weekly moving averages, and 33% below its 200-week average.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
CRMD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $7.14 | $7.87 | +10% |
| 2021 | $7.87 | $4.98 | -37% |
| 2022 | $4.98 | $4.11 | -17% |
| 2023 | $4.11 | $3.76 | -8.5% |
| 2024 | $3.76 | $8.21 | +118% |
| 2025 | $8.21 | $12.5 | +53% |
| 2026 YTD | $12.5 | $4.84 | -61% |
CRMD has finished lower in three of the last six years. It's down 61% so far in 2026.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over CRMD on returns for 2026, with the stronger performance.